Arena Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€46.52K - Cost of goods sold
€0.00 - Gross profit
€46.52K - SG&A expenses
€108.73M - R&D expenses
€361.43M - EBITDA
-€525.09M - D&A
€3.34M - EBIT
-€538.88M - Interest expenses
€2.66M - EBT
-€531.05M - Tax expenses
-€346.34K - Net income
-€531.95M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€57.72M - Changes in working capital
€19.97M - Operating cash flow
-€389.43M - Capex
€61.16M - Other investing cash flow
-€60.31M - Net investing cash flow
€276.90M - Total cash dividends paid
€0.00 - Issuance of common stock
€84.81M - Debt repayment
€0.00 - Other financing cash flow
€116.66M - Net financing cash flow
€116.66M - Foreign exchange effects
€203.33K - Net change in cash
€4.33M - Cash at end of period
€193.67M - Free cash flow
-€328.27M
Balance sheet
- Cash and cash equivalents
€193.48M - Cash and short-term investments
€474.26M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€16.37M - Total current assets
€490.62M - Property, plant & equipment
€16.48M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€138.53M - Other non-current assets
€30.43M - Total non-current assets
€185.44M - Total assets
€676.06M - Accounts payable
€11.46M - Short-term debt
€4.35M - Other current liabilities
€41.32M - Total current liabilities
€57.13M - Long-term debt
€31.15M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€7.75M - Total non-current liabilities
€38.90M - Total liabilities
€96.04M - Common stock
€5.17K - Retained earnings
-€1.83B - Other equity
-€241.23K - Total equity
€580.03M - Total liabilities and shareholders' equity
€676.06M
Company information
- Market capitalization
€0.00 - Employees
448 - Enterprise Value
-€183.36M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -1,120.0% - EBITDA margin
-
-1,128,657.4% Much worse than peer group: -2,415.9% - EBIT margin
-
-1,158,285.2% Much worse than peer group: -2,542.9% - EBT margin
-
-1,141,464.8% Much worse than peer group: -2,980.4% - Net margin
-
-1,143,403.7% Much worse than peer group: -2,591.5% - ROE
-
-91.7% Much worse than peer group: -63.8% - ROA
-
-78.7% Much worse than peer group: -23.5% - Asset turnover
-
0.0% Much worse than peer group: 44.4% - FCF margin
-
-968,525.9% Much worse than peer group: -1,976.4% - FCF yield
0.0% - Efficiency ratio
1,128,757.4% - Net sales per employee
-
€103.85 - Net income per employee
-
-€1.19M